Results 31 to 40 of about 4,811,177 (246)

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

A patient with a germline GATA2 mutation and primary myelofibrosis.

Blood Advances, 2021
First description of a patient with a germline GATA2 mutation and diagnosis of primary myelofibrosis. Development of bone marrow failure on a Janus kinase inhibitor.
C. Rütsche, E. Haralambieva, V. Lysenko, S. Balabanov, A. Theocharides   +4 more
semanticscholar   +1 more source

Correlation between Primary Myelofibrosis and the Association of Portal Thrombosis with Portal-Biliary Cavernoma: US, MDCT, and MRI Features

Journal of Gastrointestinal and Abdominal Radiology, 2021
Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo, Stefania Galassi, Salvatore Merola, Paolo Bonome, Esmeralda Conte, Elsa Iannicelli   +5 more
doaj   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review

Internal medicine, 2021
Ruxolitinib, a Janus kinase inhibitor, improves symptoms in patients with myelofibrosis. However, its association with the development of opportunistic infections has been a concern.
Asuka Ogai, K. Yagi, Fumimaro Ito, H. Domoto, T. Shiomi, K. Chin   +5 more
semanticscholar   +1 more source

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations.
A. Tefferi
semanticscholar   +1 more source

Mutations and prognosis in primary myelofibrosis [PDF]

Leukemia, 2013
Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patients and the seminal observations were validated in 396 Mayo Clinic patients.
VANNUCCHI, ALESSANDRO MARIA, Lasho TL, GUGLIELMELLI, PAOLA, BIAMONTE, FLAVIA, Pardanani A, Pereira A, Finke C, Score J, Gangat N, MANNARELLI, CARMELA, Ketterling RP, ROTUNNO, GIADA, Knudson RA, Susini MC, Laborde RR, SPOLVERINI, AMBRA, PANCRAZZI, ALESSANDRO, PIERI, LISA, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A.   +31 more
openaire   +3 more sources

Myelofibrosis and Pancytopenia Associated With Primary Hyperparathyroidism [PDF]

AACE Clinical Case Reports, 2021
Primary hyperparathyroidism (PHPT) has varied clinical presentations. Hematologic abnormalities secondary to PHPT have been described before. However, pancytopenia as the initial presentation has rarely been reported. We report a patient with PHPT who presented for evaluation of pancytopenia.Histopathology of the bone marrow at presentation is ...
Rajan, R, Paul, I, Cherian, KE, Korula, A, Hephzibah, J, Manipadam, MT, Abraham, DT, Kapoor, N, Paul, TV   +8 more
openaire   +5 more sources

Treatment of primary myelofibrosis

Turkish Journal of Hematology, 2009
Şinasi Özsoylu
doaj   +2 more sources